Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Pheast Therapeutics
Massachusetts General Hospital
M.D. Anderson Cancer Center
Seattle Children's Hospital
University of California, San Francisco
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute
Columbia University
EMD Serono
St. Jude Children's Research Hospital
Neonc Technologies, Inc.
The University of Texas Health Science Center, Houston
Jazz Pharmaceuticals
Seattle Children's Hospital
Seattle Children's Hospital
ITM Solucin GmbH
Seattle Children's Hospital
Pfizer
Mayo Clinic
AbbVie
National Cancer Institute (NCI)
Baylor College of Medicine
Plus Therapeutics
Thomas Jefferson University
Thomas Jefferson University